EGFR and non-small cell lung carcinoma: Large randomized phase III trials comparing EGFR TKIs such as gefitinib, erlotinib or afatinib with cytotoxic chemotherapy consistently demonstrated higher response rates and prolonged progression-free survival (PFS) in EGFR mutant NSCLC patients, leading to the standard treatment of EGFR TKI as first line therapy [5-8].